These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 38321333)

  • 21. Effectiveness of vortioxetine in patients with major depressive disorder and co-morbid generalized anxiety disorder in routine clinical practice: A subgroup analysis of the RELIEVE study.
    Almeida SS; Christensen MC; Simonsen K; Adair M
    J Psychopharmacol; 2023 Mar; 37(3):279-288. PubMed ID: 36377523
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vortioxetine improves physical and cognitive symptoms in patients with post-COVID-19 major depressive episodes.
    Di Nicola M; Pepe M; Montanari S; Spera MC; Panaccione I; Simonetti A; Sani G
    Eur Neuropsychopharmacol; 2023 May; 70():21-28. PubMed ID: 36808043
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vortioxetine in patients with major depressive disorder and high levels of anxiety symptoms: An updated analysis of efficacy and tolerability.
    Adair M; Christensen MC; Florea I; Loft H; Fagiolini A
    J Affect Disord; 2023 May; 328():345-354. PubMed ID: 36708956
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized, double-blind, placebo-controlled 8-week trial of the efficacy, safety, and tolerability of 5, 10, and 20 mg/day vortioxetine in adults with major depressive disorder.
    Nishimura A; Aritomi Y; Sasai K; Kitagawa T; Mahableshwarkar AR
    Psychiatry Clin Neurosci; 2018 Feb; 72(2):64-72. PubMed ID: 28858412
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized, double-blind, placebo-controlled study to assess the efficacy and safety of vortioxetine in Japanese patients with major depressive disorder.
    Inoue T; Sasai K; Kitagawa T; Nishimura A; Inada I
    Psychiatry Clin Neurosci; 2020 Feb; 74(2):140-148. PubMed ID: 31725942
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-inflammatory treatment of depression: study protocol for a randomised controlled trial of vortioxetine augmented with celecoxib or placebo.
    Fourrier C; Sampson E; Mills NT; Baune BT
    Trials; 2018 Aug; 19(1):447. PubMed ID: 30126458
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of Vortioxetine on Cognition and Fatigue in Patients with Multiple Sclerosis and Depression: A Case Series Study.
    Gil-Sanchez A; Canudes M; Valcheva P; Nogueras L; González-Mingot C; Hervás JV; Peralta S; Solana M; Brieva L
    CNS Neurol Disord Drug Targets; 2024; 23(3):395-401. PubMed ID: 36944623
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of vortioxetine in subjects with major depressive and alcohol use disorders: a 6-month retrospective analysis.
    Di Nicola M; Pepe M; Panaccione I; Moccia L; Dattoli L; Molinaro M; Sani G; Janiri L; McIntyre RS
    CNS Spectr; 2022 Feb; 27(1):73-81. PubMed ID: 32772956
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness and Safety of Vortioxetine for Major Depressive Disorder in Real-World Clinical Practice: Results from the Single-Arm RELIEVE China Study.
    Wang G; Xiao L; Ren H; Simonsen K; Ma J; Xu X; Guo P; Wang Z; Bai L; Heldbo Reines E; Hammer-Helmich L
    Neuropsychiatr Dis Treat; 2022; 18():1939-1950. PubMed ID: 36065389
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized, 8-week, double-blind, placebo-controlled trial of vortioxetine in Japanese adults with major depressive disorder, followed by a 52-week open-label extension trial.
    Inoue T; Nishimura A; Sasai K; Kitagawa T
    Psychiatry Clin Neurosci; 2018 Feb; 72(2):103-115. PubMed ID: 29160598
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and tolerability of vortioxetine (15 and 20 mg) in patients with major depressive disorder: results of an open-label, flexible-dose, 52-week extension study.
    Jacobsen PL; Harper L; Chrones L; Chan S; Mahableshwarkar AR
    Int Clin Psychopharmacol; 2015 Sep; 30(5):255-64. PubMed ID: 26020712
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Using Social Media to Help Understand Patient-Reported Health Outcomes of Post-COVID-19 Condition: Natural Language Processing Approach.
    Dolatabadi E; Moyano D; Bales M; Spasojevic S; Bhambhoria R; Bhatti J; Debnath S; Hoell N; Li X; Leng C; Nanda S; Saab J; Sahak E; Sie F; Uppal S; Vadlamudi NK; Vladimirova A; Yakimovich A; Yang X; Kocak SA; Cheung AM
    J Med Internet Res; 2023 Sep; 25():e45767. PubMed ID: 37725432
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cognitive impairment as measured by the THINC-integrated tool (THINC-it): Association with psychosocial function in major depressive disorder.
    Cha DS; Carmona NE; Subramaniapillai M; Mansur RB; Lee Y; Hon Lee J; Lee J; Rosenblat JD; Shekotikhina M; Park C; Rong C; Greer TL; Lam R; Baune BT; Harrison J; McIntyre RS
    J Affect Disord; 2017 Nov; 222():14-20. PubMed ID: 28667888
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The impact of antidepressant treatments on family functioning in adults with major depressive disorder: a post hoc comparison of vortioxetine and agomelatine.
    François C; Nielsen R; Danchenko N; Williams V; Lançon C
    Curr Med Res Opin; 2017 Jun; 33(6):1057-1066. PubMed ID: 28277865
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Successfully treated patients with vortioxetine versus venlafaxine: a simplified cost-effectiveness analysis based on a head-to-head study in Asian patients with major depressive disorder.
    Wang G; Zhao K; Reynaud-Mougin C; Loft H; Ren H; Eriksen HF; Ettrup A
    Curr Med Res Opin; 2020 May; 36(5):875-882. PubMed ID: 31990207
    [No Abstract]   [Full Text] [Related]  

  • 36. Real-world clinical outcomes and treatment patterns in patients with MDD treated with vortioxetine: a retrospective study.
    McDaniel BT; Cornet V; Carroll J; Chrones L; Chudzik J; Cochran J; Guha S; Lawrence DF; McCue M; Sarkey S; Lorenz B; Fawver J
    BMC Psychiatry; 2023 Dec; 23(1):938. PubMed ID: 38093196
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Digital Patient Reported Outcome Measures Platform for Post-COVID-19 Condition and Other Long-Term Conditions: User-Centered Development and Technical Description.
    Sivan M; Rocha Lawrence R; O'Brien P
    JMIR Hum Factors; 2023 Oct; 10():e48632. PubMed ID: 37665334
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Non-invasive brain stimulation for fatigue in post-acute sequelae of SARS-CoV-2 (PASC).
    Santana K; França E; Sato J; Silva A; Queiroz M; de Farias J; Rodrigues D; Souza I; Ribeiro V; Caparelli-Dáquer E; Teixeira AL; Charvet L; Datta A; Bikson M; Andrade S
    Brain Stimul; 2023; 16(1):100-107. PubMed ID: 36693536
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of Depression with Vortioxetine and Second Generation Antipsychotics During the Period of Remission Formation in Schizophrenia (Interim Data Analysis).
    Reznik AM; Syunyakov TS; Mudrak AV; Zakharov NB; Popova ZB; Khoroshilova AN; Khurbatova IG; Saifulina AM; Eliseenko AM; Matvievskaya TK; Khannanova AN
    Consort Psychiatr; 2023 Mar; 4(1):18-36. PubMed ID: 38239568
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness of vortioxetine for major depressive disorder in real-world clinical practice: US cohort results from the global RELIEVE study.
    Mattingly G; Brunner E; Chrones L; Lawrence DF; Simonsen K; Ren H
    Front Psychiatry; 2022; 13():977560. PubMed ID: 36683990
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.